BioSolvix Signs MOU with Catholic University Department of Surgery for Organoid Development

BioSolvix, a specialized company in alternative animal testing (CEO Choi Soo-young), announced on the 29th that it has signed a business agreement with the Department of Surgery at Catholic University College of Medicine (Chair Professor Yoon Sang-seop) for the development of organoid technology.

This agreement was made for the two institutions to mutually cooperate and conduct joint research in the field of organoid technology development for organs and cancer. A company representative stated, “Through this agreement, BioSolvix and Catholic University will share research infrastructure and technological capabilities for the development of organoid technology for organs and cancer,” adding, “Based on this, we plan to actively develop new alternative animal testing methods and also engage in patient-tailored drug screening.”

BioSolvix is a specialized company in alternative animal testing established in May. The company’s main business includes toxicity and efficacy testing using organoids of organs, efficacy testing using cancer organoids, and patient-tailored drug screening. In the future, they plan to expand research to various alternative animal testing methods beyond organoids.

Dr. Park Soon-chul, Chief of Surgery at Seoul St. Mary’s Hospital, said, “Through the agreement with BioSolvix, which possesses advanced technology, the research of surgery professors will further develop,” and added, “Ultimately, the research of the two institutions is expected to provide optimal patient-tailored services based on cellular tissues.”

BioSolvix CEO Choi Soo-young said, “Our company has collaborated across the overall organoid field, including organs and cancer, through this agreement with Catholic University,” and added, “By cooperating with the Department of Surgery at Catholic University, which consists of eight affiliated hospitals including Seoul St. Mary’s Hospital, Yeouido St. Mary’s Hospital, Uijeongbu St. Mary’s Hospital, Bucheon St. Mary’s Hospital, Eunpyeong St. Mary’s Hospital, Incheon St. Mary’s Hospital, St. Vincent’s Hospital, and Daejeon St. Mary’s Hospital, rapid technological development will be possible.” He further stated, “We plan to quickly establish multiple organoid product lines through continuous joint research going forward.”

This content was produced with the assistance of AI translation services.